Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12799291 | 0.79 | HTT (0.35) | HTTALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL16533055 | 0.77 | GSK3A (0.41) | HTTALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL15362286 | 0.77 | GSK3A (0.41) | HTTALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL24708055 | 0.76 | MTNR1A (0.38) | HTTALDH1A1SMN1; SMN2TSHRHPGD | |
| SCHEMBL13609856 | 0.74 | LMNA (0.46) | HTTALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL12799292 | 0.74 | LMNA (0.46) | HTTALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL17831027 | 0.74 | LMNA (0.46) | HTTALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL18796144 | 0.72 | GSK3A (0.37) | HTTALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL277686 | 0.72 | SMN1; SMN2 (0.39) | HTTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL2607944 | 0.72 | ALDH1A1 (0.40) | HTTALDH1A1LMNASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166717-A1 | RADIOLABELLING METHOD | GE HEALTHCARE LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166717-A1 | RADIOLABELLING METHOD | QPCT, ARF5, PAICS | HTT 2583/4885ALDH1A1 2454/4885LMNA 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.